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Purpose and Scope
Drug and Alcohol Dependence is an international journal devoted to publishing original research, scholarly reviews, commentaries, and policy analyses in the areas of
drug, alcohol, and tobacco use and dependence. Articles range from studies of the chemistry of substances of abuse, their actions at molecular and cellular sites, in vitro
and in vivo investigations of their biochemical, pharmacological, and behavioral actions, laboratory-based and clinical research in humans, substance abuse treatment and
prevention research, to studies employing methods from epidemiology, sociology, and economics. The rationale for this extensive coverage is the conviction that drug,
alcohol, and tobacco use/dependence cannot be understood in their entirety from a single perspective and that without an understanding of other areas of research, studies
by individual investigators may be limited. The goal of the journal is to provide researchers, clinicians, and policy makers access to material from all perspectives in a
single journal in a format that is understandable and which has received rigorous editorial review. The hope of its Editors is to promote mutual understanding of the many
facets of drug abuse to the beneﬁ t of all investigators involved in drug and alcohol research, and to facilitate the transfer of scientiﬁ c ﬁ ndings to successful treatment and
prevention practices. Drug and Alcohol Dependence is currently being distributed to all the members of The College on Problems of Drug Dependence, the oldest
scientiﬁ c organization in the United States concerned with the research on problems of drug dependence.
Types of Papers
 1. Full-length Reports reporting original results of research within the ﬁ eld of drug, alcohol and tobacco use and dependence.
 2. Review Articles of specialised topics within the scope of the journal. Authors who plan to submit reviews to the journal are advised to contact one of the editors to
discuss the suitability of the proposed topic.
 3. Short Communications reporting on research that has progressed to the stage where a preliminary publication is appropriate. The maximum length allowed will be
1500 words plus references and illustrations. There should be not more than 2 illustrations (ﬁ gures or tables).
Drug and Alcohol Dependence is a signatory of the Farmington Consensus Statement which is published in its entirety in Volume 48 Issue 3. Submission of a paper to
the journal will be taken as evidence that the authors have complied with the tenets set forth in that statement. When articles are submitted, a written statement that each
listed author has contributed substantially to the work and concurs with the submission should be included. This implies that a copy of the ﬁ nal manuscript has been
approved by all authors and tacitly and explicitly by the responsible authorities in the laboratories where the work was carried out. Authors should also assure the journal
in a written statement that there is no known conﬂ ict of interest. If authors have any questions concerning a possible conﬂ ict of interest, they should consult the Editor
prior to submission. Authors should reveal explicitly in the manuscript all funding sources that enabled the studies to be conducted and the manuscript prepared, and that
the study was conducted with the appropriate ethical safeguards. Submission of a paper to Drug and Alcohol Dependence is also understood to imply that it has not
previously been published and that it is not being published elsewhere, including in electronic form. The accepted abbreviation for Drug and Alcohol Dependence for
bibliography citation is Drug Alcohol Depend. If accepted, the manuscript shall not be published elsewhere in the same form or electronically, in either the same or
another language, without the consent of the Editor and Publisher. Authors should be aware that the journal has deﬁ ned policies for response to attempted or actual
instances of duplicate publication, plagiarism, or scientiﬁ c fraud.
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